Synthetic Biologics Inc (SYN) : Analyst Rating Update

Synthetic Biologics Inc (SYN) : 4 brokerage houses believe that Synthetic Biologics Inc (SYN) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.2.

Synthetic Biologics Inc (SYN) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $10 and the lowest price target forecast is $8. The average forecast of all the analysts is $9 and the expected standard deviation is $0.82.

Synthetic Biologics Inc (NYSEMKT:SYN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.78 and $1.77 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.87. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.83, notching a gain of 1.67% for the day. The total traded volume was 472,970 . The stock had closed at $1.80 on the previous day.

The company shares have dropped -34.78% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $4.32 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $1.95 and the 200 Day Moving Average price is recorded at $1.96.

Synthetic Biologics, Inc. is a clinical-stage biotechnology company. The Company is developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.